Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Päätekijät: Antonio Lacquaniti (Tekijä), Patrizio Pasqualetti (Tekijä), Teresa Casuscelli di Tocco (Tekijä), Susanna Campo (Tekijä), Stefania Rovito (Tekijä), Maurizio Bucca (Tekijä), Antonino Ragusa (Tekijä), Paolo Monardo (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...